-
Portrait | 2024.05.21
Philippe Bousso: harnessing immune responses to combat cancer
Philippe Bousso, an immunologist and technophile with insatiable curiosity, is constantly tackling new challenges in his efforts to combat cancer. Like the characters in the sci-fi film Fantastic Voyage, he and his team use cutting-edge in vivo technologies to observe the ways in which the immune system wages war on cancer cells. For Philippe, creativity and innovation pave the way for new...
-
Document de presse | 2015.10.28
The Institut Pasteur and Chan Soon-Shiong Institute for Molecular Medicine Partner to Form Global Genomics Center
Paris, France and Los Angeles, CaliforniaThe Chan Soon-Shiong Institute for Molecular Medicine (CSSIOMM) and the Institut Pasteur today announced a partnership to establish The Pasteur Global Health Genomics Center (PGHGC). The aim of the PGHGC is to advance genomic research utilizing next-generation patient information systems needed to support the acquisition and usage of high-quality...
-
Document de presse | 2023.02.20
HIV: third case in the world of probable cure after a bone marrow transplant
Forty years after the discovery of HIV in 1983 at the Institut Pasteur, 38.4 million people were living with the virus worldwide in 2021.[1] Only two cases of people being cured had previously been described: the Berlin patient in 2009 and the London patient in 2019. The IciStem consortium, whose members include Asier Sáez-Cirión's team at the Institut Pasteur, in collaboration with Düsseldorf...
-
Article | 2019.06.20
Cancer and microbes
Identifying and combating the risk factors behind tumor development.
-
Document de presse | 2016.03.21
A genomic study of epidemic dysentery: how Europe exported a scourge worldwide
Scientists at the Institut Pasteur and its International Network, the Wellcome Trust Sanger Institute (Cambridge, United Kingdom) and several international institutions have just published an exceptionally wide-ranging study tracing the history of the bacillus responsible for epidemic dysentery – one of the worst scourges to afflict humans throughout the 18th and 19th centuries. This vast...
-
Document de presse | 2020.04.24
Development and evaluation of four serological assays to detect SARS-CoV-2 antibodies and two assays to detect neutralizing antibodies
Approximately four months after the initial description of cases of atypical pneumonia in Wuhan, China, in December 2019, COVID-19 had become a major pandemic threat. By April 12, 2020, around half of the world's population was in lockdown, with 1.8 million officially diagnosed cases. Scientists from the Institut Pasteur, the CNRS, Inserm and Université de Paris conducted a pilot study to...
-
Document de presse | 2016.01.07
University of Maryland School of Medicine researcher Jacques Ravel receives prestigious international science award
Research Focuses on the Intersection of Women’s Health and the Microbiome Jacques Ravel, PhD, Professor of Microbiology and Immunology, as well as Associate Director for Genomics at the Institute for Genome Sciences (IGS), both at the University of Maryland School of Medicine, has been named a 2015-2017 Blaise Pascal International Research Chair, one of the most prestigious European science...
-
Document de presse | 2015.05.25
Kurma Partners announces the launch of its third fund Kurma Diagnostics (KDx)
The European Investment Fund (EIF), Fonds National d’Amorçage (FNA) managed by Bpifrance as part of the French government’s Investments for the future (“Investissements d’Avenir”) program, Institut Pasteur, and BNP Paribas are participating in the first closing (€33M). Press release Paris, May 26, 2015 Kurma Diagnostics: the first Venture Capital...
-
Document de presse | 2013.12.18
Molecular marker discovered for detecting artemisinin-resistant forms of malaria
Scientists at the Institut Pasteur in Paris, the Institut Pasteur in Cambodia, the French National Center for Scientific Research (CNRS), and the U.S. National Institutes of Health (NIAID/NIH) have identified a molecular marker for detecting malaria parasites with resistance to artemisinin derivatives (major components in antimalarial medicine or drug treatments currently recommended by the World...
-
Document de presse | 2013.02.06
Treatment of Cutaneous Leishmaniasis: Study of Phase III Shows Antibiotic Cream Has High Cure Rate, Few Side Effects
An international research partnership from Tunisia, France and the United States has demonstrated a high cure rate and remarkably few side effects in treating patients with cutaneous leishmaniasis (CL) with an antibiotic cream. CL is a parasitic disease that causes disfiguring lesions and affects 1.5 million people worldwide annually, including the socio-economically disadvantaged in the...